Evidence mapPaperPMID 31865474Full record

SynthesisJournal of pharmacokinetics and pharmacodynamics2020

Comparison of the gamma-Pareto convolution with conventional methods of characterising metformin pharmacokinetics in dogs.

Carl A Wesolowski, Surajith N Wanasundara, Paul S Babyn, Jane Alcorn

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in Journal of pharmacokinetics and pharmacodynamics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Metformin disposition-A 40-year-old mystery.British journal of clinical pharmacology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Carl A WesolowskiDepartment of Medical Imaging, Royal University Hospital, College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada. carl.wesolowski@gmail.com.ORCID 0000-0003-0134-9346
Surajith N WanasundaraDepartment of Medical Imaging, Royal University Hospital, College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.
Paul S BabynDepartment of Medical Imaging, Royal University Hospital, College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.
Jane AlcornCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK, S7N 2Z4, Canada.
Royal University Hospital · CAUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A model was developed for long term metformin tissue retention based upon temporally inclusive models of serum/plasma concentration ([Formula: see text]) having power function tails called the gamma-Pareto type I convolution (GPC) model and was contrasted with biexponential (E2) and noncompartmental (NC) metformin models. GPC models of [Formula: see text] have a peripheral venous first arrival of drug-times parameter, early [Formula: see text] peaks and very slow washouts of [Formula: see text]. The GPC, E2 and NC models were applied to a total of 148 serum samples drawn from 20 min to 72 h following bolus intravenous metformin in seven healthy mongrel dogs. The GPC model was used to calculate area under the curve (AUC), clearance ([Formula: see text]), and functions of time, f(t), for drug mass remaining (M), apparent volume of distribution ([Formula: see text]), as well as [Formula: see text] for [Formula: see text], [Formula: see text] and [Formula: see text]. The GPC models of [Formula: see text] yielded metformin [Formula: see text]-values that were 84.8% of total renal plasma flow (RPF) as estimated from meta-analysis. The GPC [Formula: see text]-values were significantly less than the corresponding NC and E2 [Formula: see text]-values of 104.7% and 123.7% of RPF, respectively. The GPC plasma/serum only model predicted 78.9% drug [Formula: see text] average urinary recovery at 72 h; similar to prior human urine drug [Formula: see text] collection results. The GPC model [Formula: see text] of [Formula: see text], [Formula: see text] and [Formula: see text], were asymptotically proportional to elapsed time, with a constant limiting [Formula: see text] ratio of M/C averaging 7.0 times, a result in keeping with prior simultaneous [Formula: see text] and urine [Formula: see text] collection studies and exhibiting a rate of apparent volume growth of [Formula: see text] that achieved limiting constant values. A simulated constant average drug mass multidosing protocol exhibited increased [Formula: see text] and [Formula: see text] with elapsing time, effects that have been observed experimentally during same-dose multidosing. The GPC heavy-tailed models explained multiple documented phenomena that were unexplained with lighter-tailed models.

Indexed as

AnimalsArea Under CurveDogsFemaleHumansMaleMetforminMetforminClearanceDrug massLoading dose regimenMathematical modelling pdfMetforminPharmacokineticsSerum concentration

Identifiers

PMID31865474
PMCPMC7040082
OpenAlexW2996466516

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.